FDA’s “Complete Response” Letters May Not Be Complete Enough For Firms

FDA's "complete response" final regulations finally do away with negative connotations of the "not approvable" label used by the agency since the 1990s, but they will not provide more certainty for sponsors about how to answer FDA's problems with an application